Dr Pavan Ganapati Bhat resigns as Director & Executive Vice President (Technical Operations) of Natco Pharma
Telangana: Natco Pharma has announced the resignation of Dr Pavan Ganapati Bhat as Director & Executive Vice President (Technical Operations) of the Company due to new career opportunity outside the Company.
Dr Pavan joined Natco Pharma in 2016 as Executive Vice President - Technical Operations. Prior to his tenure at Natco, he worked at Mylan in the USA, focusing on Transdermal R&D, 050 R&D, and Corporate & Business Development.
NATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.
